Forecasting Patient Outcomes in the Management of Hyperlipidemia

Long-term Persistence in Use of Statin Therapy in Elderly Patients

“…They make it clear that one cannot assume that long-term persistence in typical settings will approach the levels observed in prospective trials. Accordingly, predictions of population-wide health benefits of statin therapy 38 based on these trials may be overly optimistic given the poor persistence we observed. Recent meta-analyses suggest that the most effective persistence-enhancing interventions for long-term treatments consist of combinations of more convenient care, information, counseling, reminders, reinforcement, and other forms of supervision or attention.…”

Practice Patterns in Treating High-Risk Patients with Hyperlipidemia at a Northeast Tennessee University Clinic

“…11 Recent studies revealed that only about 20% of high-risk patients reach their target LDL cholesterol level in primary care clinic settings, 8 although this number varied widely. 12 Data reveal that cardiologists document and treat elevated LDL cholesterol more often than primary care physicians. When dealing with high-risk populations, target LDL level is reached more often in lipid clinic settings (about 80%) compared with primary care clinics.…”

Development of a Parametric Simulation Model for Forecasting Goal-Oriented Treatment Outcomes

“…Nevertheless, application of the mean BP reduction from a clinical trial to the general population may be inappropriate because the variation associated with mean BP reduction was not accounted for. Unfortunately, this "mean value approach" has also been recommended and implemented in the area of hyperlipidemia in which a mean low-density lipoprotein (LDL) percentage reduction was applied to the US population to estimate the impact of population-based LDL reduction [4,29]. The authors had remarked that the appropriateness of using a mean percentage of LDL reduction increases as the amount of deviation from the mean decreases [4].…”

“…Treatment guidelines for chronic diseases are often subject to revision as newer and more reliable disease-specific data become available [1][2][3]. The use of quality indicators to measure and evaluate health-care delivery has led to a rapid growth in the number of treatment-to-goal (TTG) analyses [4][5][6][7][8][9]. Decision makers in managed care are increasingly interested in assessing a drug's potential ability to achieve predefined treatment goals before rendering formulary or reimbursement decisions.…”